MaxCyte, Inc. (MXCT) Earnings Call Analysis
NASDAQ · Healthcare · Medical Devices
Earnings Reports
-
MaxSight (MXCT) Q1 2026: OpEx Drops $7M, Unlocking Cash Burn Flexibility Amid SPL Portfolio Stability
May 13, 2026
-
MaxSight (MXCT) Q4 2025: $4M SPL Headwind Reshapes 2026 Base, DTX Launch Targets New Growth
March 25, 2026
-
MaxCyte (MXCT) Q3 2025: Restructuring Delivers $17M Cost Savings as SPL Pipeline Stays Resilient
November 13, 2025
-
MaxSight (MXCT) Q2 2025: Core Revenue Guidance Cut by $5M as Customer Consolidations Hit Outlook
August 06, 2025
-
MaxCyte (MXCT) Q1 2025: SPL Revenue Hits $2.1M as SecureDx Integration Expands TAM
July 04, 2025